ArticleBlood advances2023
JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk.Blood · 2024Pooled it
- Article
- Mathematical modeling ofProceedings of the National Academy of Sciences of the United States of America · 2026Article
- A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.Leukemia · 2026Review
- Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners.Blood advances · 2026Review
- Prevalence of the JAK2 V617F Mutation in Patients with Non-Cardioembolic Stroke.Journal of atherosclerosis and thrombosis · 2026Article
- JAK2 pathogenic variants in ischemic stroke: low prevalence and pre-screening model.Journal of neurology · 2026Article
- The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all-cause mortality.Journal of internal medicine · 2026Article
- Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report.Frontiers in immunology · 2026Article
- Palatal-Lingual-Facial Myoclonus Due to Acute Cortical Infarction in JAK2V617F Positive Myelodysplastic Syndrome.Movement disorders clinical practice · 2025Article
- Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women.Journal of the American College of Cardiology · 2025Article
- Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients.British journal of haematology · 2025Observational
- Neutrophil-to-Lymphocyte ratio as surrogate for JAK2Blood cancer journal · 2025Article
- Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2025Review
- Article
- Myeloproliferative Neoplasms and Dementia Risk: A Population-Based Cohort Study.European journal of haematology · 2025Article
- Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report.Frontiers in cardiovascular medicine · 2025Article
- Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice.The Journal of clinical investigation · 2024Article
- Clonal Hematopoiesis from a Diagnostic Perspective: 10 Years of CHIP.Molecular diagnosis & therapy · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke has a high recurrence rate despite treatment. This underlines the significance of investigating new possible cerebrovascular risk factors, such as the acquired gene mutation JAK2V617F found in 3.1% of the general population. We aimed to investigate the prevalence of the JAK2V617F mutation in a population with ischemic stroke compared with that in matched controls. We enrolled 538 consecutive Danish patients with ischemic stroke (mean age, 69.5 ± 10.9 years; 39.2% female) within 7 days of symptom onset. Using multiple-adjusted conditional logistic regression analysis, we compared the prevalence of JAK2V617F with that in age- and sex-matched controls free of ischemic cerebrovascular disease (ICVD) from the Danish General Suburban Population Study. DNA was analyzed for JAK2V617F mutation using sensitive droplet digital polymerase chain reaction in patients and controls. Of the 538 patients with ischemic stroke, 61 (11.3%) had JAK2V617F mutation. There were no differences in patient demographics or cerebrovascular comorbidities between the patients with and without mutations. Patients with ischemic stroke were more likely to have the JAK2V617F mutation than matched controls, in whom the JAK2V617F prevalence was 4.4% (odds ratio, 2.37; 95% confidence interval, 1.57-3.58; P < .001). A subanalysis stratified by smoking history revealed that the association was strongest in current smokers (odds ratio, 4.78; 95% confidence interval, 2.22-10.28; P < .001). Patients with ischemic stroke were 2.4 times more likely to have the JAK2V617F mutation than matched controls without ICVD when adjusting for other cerebrovascular risk factors. This finding supports JAK2V617F mutation as a novel cerebrovascular risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.